אינרביק - Inrebic
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01EJ Janus-associated kinase (JAK) inhibitors |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | פ××× - PER OS |
| צ×רת ××× ×× | קפס×××ת, CAPSULES ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | INREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) |
| ת×× ×ת:× ×ª×× × ×¡×/××× ×¨××ק - Inrebic | |
| ×ת××××ת × ×× | Contraindications |
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction |
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation |
| פר×ק×××× ×××§× | Pharmacodynamic Properties |
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××× ×¨××ק ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | BRISTOL-MYERS SQUIBB COMPANY, USA |
| ×©× ××¢× ×ר×ש×× | BRISTOL, MYERS SQUIBB (ISRAEL) LIMITED, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 7/2020. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 12/07/2025 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־12 ביולי 2025 ב־16:31